A new paradigm for antiangiogenic therapy through controlled release of bevacizumab from PLGA nanoparticles
Author:
Publisher
Springer Science and Business Media LLC
Subject
Multidisciplinary
Link
http://www.nature.com/articles/s41598-017-03959-4.pdf
Reference56 articles.
1. Weiner, G. J. Building better monoclonal antibody-based therapeutics. Nat. Rev. Cancer 15, 361–370, doi: 10.1038/nrc3930 (2015).
2. Ecker, D. M., Jones, S. D. & Levine, H. L. The therapeutic monoclonal antibody market. mAbs 7, 9–14, doi: 10.4161/19420862.2015.989042 (2015).
3. Ferrara, N. & Davis-Smyth, T. The biology of vascular endothelial growth factor. Endocr. Rev. 18, 4–25, doi: 10.1210/edrv.18.1.0287 (1997).
4. Li, F., Hurley, B., Liu, Y., Leonard, B. & Griffith, M. Controlled release of bevacizumab through nanospheres for extended treatment of age-related macular degeneration. Open Ophthalmol. J. 6, 54–58, doi: 10.2174/1874364101206010054 (2012).
5. Abrishami, M. et al. Preparation, characterization, and in vivo evaluation of nanoliposomes-encapsulated bevacizumab (avastin) for intravitreal administration. Retina 29, 699–703, doi: 10.1097/IAE.0b013e3181a2f42a (2009).
Cited by 101 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Improving glioma drug delivery: A multifaceted approach for glioma drug development;Pharmacological Research;2024-10
2. Advances in targeted nano-delivery of bevacizumab using nanoparticles: Current insights, innovations, and future perspectives;Journal of Drug Delivery Science and Technology;2024-09
3. Treatment avenues for age-related macular degeneration: Breakthroughs and bottlenecks;Ageing Research Reviews;2024-07
4. Intravitreal therapeutic nanoparticles for age-related macular degeneration: Design principles, progress and opportunities;Advances in Colloid and Interface Science;2024-07
5. Multifunctional nano-in-micro delivery systems for targeted therapy in fundus neovascularization diseases;Journal of Nanobiotechnology;2024-06-20
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3